

Title (en)  
THE USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

Title (de)  
DIE VERWENDUNG VON PROTEASOM HEMMERN ZUR BEHANDLUNG VON KREBS, ENTZÜNDUNG, AUTOIMMUNKRANKHEITEN, TRANSPLANTABSTOSSUNG UND SEPTISCHEM SCHOCK

Title (fr)  
UTILISATION D'INHIBITEURS DE PROTEASOMES DANS LE TRAITEMENT DU CANCER, DE L'INFLAMMATION, DE MALADIES AUTOIMMUNES, DU REJET DU GREFFON ET DU CHOC SEPTIQUE

Publication  
**EP 0967976 A1 20000105 (EN)**

Application  
**EP 98951135 A 19981029**

Priority  
• CA 9801010 W 19981029  
• CA 2219867 A 19971031

Abstract (en)  
[origin: WO9922729A1] The present invention relates to compositions comprising proteasome inhibitors, such as lactocystin and analogues thereof. These compositions are used for the following purposes: (1) to disrupt mitochondrial function (useful against cancer, inflammation, adverse immune reaction and hyperthyroidism), (2) to disrupt nitric oxide synthesis (useful against inflammation and septic shock), and (3) to reverse ongoing adverse immune reactions, such as autoimmune diseases and graft rejection. In the later case, the compositions are administered once the patient's T cells are mostly activated. Proteasome inhibitors can also be combined to immuno-suppressive drugs like rapamycin, cyclosporin A and FK506. Finally, a method for screening a compound having a proteasome inhibition activity is also disclosed and claimed.

IPC 1-7  
**A61K 31/40**

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4015** (2006.01); **A61K 31/436** (2006.01); **A61K 31/445** (2006.01); **A61K 31/7042** (2006.01); **A61K 38/13** (2006.01); **A61K 45/00** (2006.01); **A61P 5/14** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01)

CPC (source: EP)  
**A61K 31/00** (2013.01); **A61K 31/40** (2013.01); **A61K 31/436** (2013.01); **A61K 31/445** (2013.01); **A61K 38/13** (2013.01); **A61P 5/14** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/06** (2017.12); **G01N 2333/96425** (2013.01)

Citation (search report)  
See references of WO 9922729A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9922729 A1 19990514**; AU 770798 B2 20040304; AU 9731898 A 19990524; CA 2219867 A1 19990430; EP 0967976 A1 20000105; JP 2001508465 A 20010626

DOCDB simple family (application)  
**CA 9801010 W 19981029**; AU 9731898 A 19981029; CA 2219867 A 19971031; EP 98951135 A 19981029; JP 52505499 A 19981029